A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
Drugmaker Merck reported a better-than-expected first-quarter profit on Tuesday, helped by a more than 150 percent rise in sales of cancer drug Keytruda.
Merck is increasingly reliant on the blockbuster medicine, which is positioned to become the leading player in a new generation of oncology treatments and rival Bristol-Myers Squibb's Opdivo.
Both drugs harness the body's immune system to recognize and fight cancer cells, but last month's survival data from trials of the treatments gave Keytruda an edge over Opdivo, according to industry experts.
Keytruda raked in sales of $1.46 billion in the quarter, ahead of $1.40 billion estimated by analysts, according to Thomson Reuters.
Revenue from the drug accounted for nearly 15 percent of Merck's total sales, helped by its expanded approval to treat various forms of cancer.
Sales of Bristol-Myers Squibb's Opdivo surged 34 percent to $1.51 billion in the latest quarter.
Merck raised its full-year forecast for adjusted earnings to between $4.16 and $4.28 per share from between $4.08 and $4.23 per share estimated previously.
Net income fell 52.5 percent to $736 million, or 27 cents per share, hurt by a $1.4 billion charge related to a collaboration with Eisai Co Ltd, the company said.
Excluding items, Merck earned $1.05 per share, ahead of analysts' estimates of $1 per share .
Revenue rose 6.4 percent to $10.04 billion, but missed estimates of $10.11 billion.
Merck's shares rose 1.1 percent to $59.50 before the bell.